Page last updated: 2024-11-05

bromobenzene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID7961
CHEMBL ID16068
CHEBI ID3179
SCHEMBL ID1542
MeSH IDM0100237

Synonyms (82)

Synonym
MLS000515541
smr000112021
nci-c55492
phenyl bromide
nsc6529
benzene, bromo-
wln: er
monobromobenzene
nsc-6529
phbr
CHEBI:3179 ,
c6h5br
bromobenzene, >=99.5% (gc)
bromo-benzene
inchi=1/c6h5br/c7-6-4-2-1-3-5-6/h1-5
NCGC00091842-01
un2514
hsdb 47
nsc 6529
ai3-09059
ccris 5887
einecs 203-623-8
bromobenzene ,
108-86-1
bromobenzene, analytical standard
NCGC00091842-02
bromobenzene [un2514] [flammable liquid]
bromobenzene, reagentplus(r), 99%
MLS002415720
B0439
CHEMBL16068
AKOS000120123
A801934
bromanylbenzene
NCGC00091842-03
NCGC00091842-04
bromo benzene
co4d5j547l ,
unii-co4d5j547l
tox21_200849
cas-108-86-1
dtxsid5024637 ,
NCGC00258403-01
dtxcid304637
4-bromobenzene
HMS2269P12
FT-0617692
FT-0617909
FT-0623223
bromobenzol
bromobenzene [mi]
bromobenzene [hsdb]
STL264221
SCHEMBL1542
3-bromobenzene
1-bromobenzene
1-bromo-benzene
brombenzol
2-bromobenzene
phenylbromide
brombenzene
bromobezene
mfcd00000056
un 2514
STR00651
mfcd00000055
J-519941
J-002199
F1908-0102
BR1026
bromobenzene, lr, >=99%
bromobenzene, for synthesis, 99.5%
bromobenzene 100 microg/ml in methanol
1-bromobenzene; bromobenzene; bromobenzol; monobromobenzene; nsc 6529; phenyl bromide
64646-03-3
Q410597
BCP26654
BCP30008
bromo(2h5)benzene pound>>pentadeuterophenyl bromide
SY061516
bromobenzene--d4
EN300-19359

Research Excerpts

Overview

Bromobenzene is a well-known environmental toxin which causes liver and kidney damage through CYP450-mediated bio-activation to generate reactive metabolites and, consequently, oxidative stress. It also causes centrilobular necrosis.

ExcerptReferenceRelevance
"Bromobenzene is an environmental toxin which causes hepatotoxicity, and the secondary metabolites on biotransformation cause nephrotoxicity. "( Pre-treatment with Beta Carotene Gives Protection Against Nephrotoxicity Induced by Bromobenzene via Modulation of Antioxidant System, Pro-inflammatory Cytokines and Pro-apoptotic Factors.
Akkara, PJ; Sabina, EP, 2020
)
2.23
"Bromobenzene is a well-known environmental toxin which causes liver and kidney damage through CYP450-mediated bio-activation to generate reactive metabolites and, consequently, oxidative stress. "( Assessment of hepatoprotective and nephroprotective potential of withaferin A on bromobenzene-induced injury in Swiss albino mice: possible involvement of mitochondrial dysfunction and inflammation.
Sabina, EP; Vedi, M, 2016
)
2.1
"Bromobenzene is a hepatotoxicant that causes centrilobular necrosis. "( Macromolecular weight specificity in covalent binding of bromobenzene.
Dent, JG; Sun, JD, 1984
)
1.96

Effects

Bromobenzene has proven to be a valuable tool in efforts to unravel the complexities involved in chemical- induced toxicities. Bromobenzne metabolites have been determined in incubations of hepatocytes isolated from untreated, phenobarbital-treated and beta-naphthoflavone-treated rats.

ExcerptReferenceRelevance
"Bromobenzene has since proven to be a valuable tool in efforts to unravel the complexities involved in chemical- induced toxicities."( The contribution of bromobenzene to our current understanding of chemically-induced toxicities.
Lau, SS; Monks, TJ, 1988
)
1.32
"Bromobenzene metabolites have been determined in incubations of hepatocytes isolated from untreated, phenobarbital-treated, and beta-naphthoflavone-treated rats. "( Bromobenzene metabolism in isolated rat hepatocytes. 18O2 incorporation studies.
Billings, RE; Dankovic, D; Seifert, W; Stillwell, WG, 1985
)
3.15

Treatment

Bromobenzene treatment resulted in 29 +/- 4.4% hepatic lobule necrosis localized in the zone 3 hepatocytes. The bromobenzene-pretreated animals exhibited in basal conditions a lower bile flow (44%) than that of the controls.

ExcerptReferenceRelevance
"Bromobenzene treatment resulted in significant (P< 0.05) decreases in the activities of antioxidant enzymes such as catalase, superoxide dismutase, glutathione-S-transferase and glutathione peroxidase as well as total reduced glutathione. "( Protective role of Triphala, an Indian traditional herbal formulation, against the nephrotoxic effects of bromobenzene in Wistar albino rats.
Baskaran, UL; Mahaboobkhan, R; Martin, SJ; Prince, SE, 2015
)
2.07
"Bromobenzene treatment decreased the hepatic microsomal dealkylation of decreased the hepatic microsomal dealkylation of pentoxyresorufin in a dose-dependent manner."( Potentiation of bromobenzene-induced pneumotoxicity by phenobarbital as determined by bronchoalveolar lavage fluid analysis.
Carlson, GP; Day, BJ; DeNicola, DB, 1992
)
1.35
"Bromobenzene treatment did not alter the immunochemical properties of biliverdin reductase variants, as judged by the similarity of isoelectric focusing patterns of preparations on a Western blot using antibody raised against a rat liver total biliverdin reductase preparation."( Bromobenzene-mediated alteration in activity and electrophoretic pattern of biliverdin reductase variants in rat kidney.
Huang, TJ; Maines, MD, 1990
)
2.44
"Bromobenzene treatment resulted in 29 +/- 4.4% hepatic lobule necrosis localized in the zone 3 hepatocytes."( The role of acinar zone 3 hepatocytes in bile formation: influence of bromobenzene treatment on bile formation in the rat.
Dionne, S; Plaa, GL; Russo, P; Tuch-Weber, B; Yousef, IM, 1990
)
1.23
"When bromobenzene treatment was prolonged to 72 hours, the concentrations of the enzyme in the bone marrow and in the liver were reduced proportionally to the decrease in the enzyme activity."( Reduction of delta-aminolevulinate dehydratase concentration by bromobenzene in rats.
Fujita, H; Ishihara, N, 1988
)
0.97
"The bromobenzene-pretreated animals exhibited in basal conditions a lower bile flow (44%) than that of the controls, with a smaller decrease in bile salt output (27%) and sodium output (29%), whereas no modification in endogenous bilirubin excretion was observed."( Heterogeneity of rabbit hepatocytes for bile secretion after acinar zone 3 damage induced by bromobenzene. Effect of bilirubin and bile salt infusions.
Esteller, A; González, J, 1985
)
0.97
"Pretreatment with bromobenzene reduced the 0- to 6-h urinary excretion of all metabolites after the challenge dose; this effect was virtually reversed by OTCA."( Effect of a cysteine prodrug (L-2-oxothiazolidine-4-carboxylic acid) on the metabolism and toxicity of bromobenzene: a repeated exposure study.
Brodeur, J; Goyal, R, 1987
)
0.81

Toxicity

Bromobenzene (BB) is a classic example of this behavior. Study suggests that the hepatoprotective effect of zinc against bromobazene toxicity does not involve altered binding of the toxic metabolite to glutathione or metallothionein.

ExcerptReferenceRelevance
" For BB, both the toxic effect and the protective influence of zinc were apparent 24 h following administration."( Protective effect of zinc in the hepatotoxicity of bromobenzene and acetaminophen.
Piotrowski, JK; Swietlicka, EA; Szymańska, JA, 1991
)
0.53
" One potential mechanism by which phentolamine may diminish the bromobenzene-induced hepatotoxicity is by a direct or indirect interference with the metabolism of bromobenzene to toxic metabolites."( Antagonism of bromobenzene-induced hepatotoxicity by phentolamine: evidence for a metabolism-independent intervention.
Gandy, J; Harbison, RD; Hinson, JA; James, RC; Kerger, BD; Roberts, SM, 1988
)
0.87
" These studies suggest that the hepatoprotective effect of zinc against bromobenzene toxicity does not involve altered binding of the reactive toxic metabolite to glutathione or metallothionein, but it may be mediated by the inhibitory effect of zinc on the microsomal cytochrome P-450-dependent drug metabolizing system."( Amelioration of bromobenzene hepatotoxicity in the male rat by zinc.
McMillan, DA; Schnell, RC, 1985
)
0.85
" The urinary excretion of toxic doses of bromobenzene was nonlinear, based on the quantitative composition of various urinary metabolites."( Dose-dependent metabolic excretion of bromobenzene and its possible relationship to hepatotoxicity in rats.
Brodeur, J; Chakrabarti, S, 1984
)
0.8
"Nine chemicals, with a range from extremely to slightly toxic, were used to measure the oral LD50 in both fasted (24-h) and non-fasted rats."( The effects of fasting on the acute oral toxicity of nine chemicals in the rat.
Dashiell, OL; Kennedy, GL, 1984
)
0.27
", 30 min before, and every 6 hr after, the administration of bromobenzene) did not modify the disappearance curves of unchanged bromobenzene from plasma and liver, and did not modify the amount of bromobenzene metabolites covalently bound to hepatic proteins 1-24 hr after the administration of a toxic dose of bromobenzene (0."( Protective effect of 16,16-dimethyl prostaglandin E2 on the hepatotoxicity of bromobenzene in mice.
Babany, G; Degott, C; Funck-Brentano, C; Letteron, P; Pessayre, D; Tinel, M, 1984
)
0.74
"For many acute-acting chemicals, toxic responses observed in vivo correlate strongly with metabolic activation and macromolecular covalent binding (CVB) observed in vitro and often in vivo; bromobenzene (BB) is a classic example of this behavior."( Correlation of metabolism, covalent binding and toxicity for a series of bromobenzene derivatives using rat liver slices in vitro.
Brendel, K; Fisher, R; Hanzlik, RP, 1993
)
0.71
" Results from these studies suggested that a highly toxic arene oxide intermediate of 4-bromobenzene formed as the result of mixed function oxidase (MFO)-mediated metabolism may play an important role in the development toxicity of 4-bromobenzene in vitro."( Evaluation of the developmental toxicity of 4-bromobenzene using frog embryo teratogenesis assay--Xenopus: possible mechanisms of action.
Fort, DJ; Propst, TL; Stover, EL, 1996
)
0.77
" A screening assay has been developed based on protection of human liver-derived HepG2 cells against toxic damage."( Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay.
Hughes, RD; McFarlane, IG; Thabrew, MI, 1997
)
0.3
" We examined the generality of this pattern in livers of rats given a minimally toxic dose of an hepatotoxin and in liver biopsy samples from patients who had taken overdoses of acetaminophen."( Zonal location of compensatory hepatocyte proliferation following chemically induced hepatotoxicity in rats and humans.
Archer, MC; Cameron, RG; Lee, VM,
)
0.13
" Thus, the mechanism by which pretreatment with AGE protects against BB hepatotoxicity involves both an elevation of hepatic GSH content, and a GSH sparing effect, possibly due to conjugation of organosulphur compounds in AGE with toxic BB metabolites."( Treatment with aged garlic extract protects against bromobenzene toxicity to precision cut rat liver slices.
Billington, D; Rahman, K; Wang, BH; Zuzel, KA, 1999
)
0.55
"In the field of gene expression analysis, DNA microarray technology has a major impact on many different areas including toxicogenomics, such as in predicting the adverse effects of new drug candidates and improving the process of risk assessment and safety evaluation."( Relationship between hepatic gene expression profiles and hepatotoxicity in five typical hepatotoxicant-administered rats.
Kato, H; Katoh, M; Minami, K; Nakajima, M; Narahara, M; Saito, T; Sugiyama, H; Tomita, H; Yokoi, T, 2005
)
0.33
" Pre-treatment with different doses of ginger extract prior to BB-treatment alleviated its toxic effects on the tested parameters in the three animal groups."( Protective effect of ginger extract against bromobenzene-induced hepatotoxicity in male rats.
El-Sharaky, AS; Eweda, SM; Kamel, MA; Newairy, AA, 2009
)
0.61
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Dosage Studied

The pathways from bromobenzene to phenols and to sulfur-containing metabolites derived from premercapturic acids show species and dosage variation. Several examples of the utility of this approach from toxicological studies are presented.

ExcerptRelevanceReference
" In a dose ranging study, adult male rats were treated daily for 4 days with phenobarbital (80 mg/kg, ip) and on the fifth day were dosed with 0, 2, 3, or 4 mmoles/kg, ip, bromobenzene."( Potentiation of bromobenzene-induced pneumotoxicity by phenobarbital as determined by bronchoalveolar lavage fluid analysis.
Carlson, GP; Day, BJ; DeNicola, DB, 1992
)
0.82
" To explore the biosynthetic origin of the bromonohydroxyphenyl mercapturic acids, rats were separately dosed intraperitoneally with synthetic racemic 2-, 3-, or 4-bromophenyl mercapturic acid, or biosynthetic L-(-)-4-bromophenyl mercapturic acid, or a biosynthetic mixture of the 3,4- and 4,3-premercapturic acids from bromobenzene, and their urine (0-24 hr) analyzed by alkaline permethylation and GC/MS."( Bromo(monohydroxy)phenyl mercapturic acids. A new class of mercapturic acids from bromobenzene-treated rats.
Hanzlik, RP; Zheng, J,
)
0.53
" To search for them, phenobarbital-induced Sprague-Dawley rats were dosed (0."( Dihydroxylated mercapturic acid metabolites of bromobenzene.
Hanzlik, RP; Zheng, J,
)
0.39
" A linear relationship was observed between the dosage of BB administered and BB-GSH excreted into bile, up to a dosage of 250 mumol/kg of BB."( Bromobenzene-glutathione excretion into bile reflects toxic activation of bromobenzene in rats.
Klaassen, CD; Madhu, C, 1992
)
1.73
" The high dosage regimen (10 mg/kg per dose) of phentolamine or idazoxan that had been found to be hepatoprotective in earlier studies potentiated this hypothermia and more than doubled the net decrease in core body temperature experienced by the animals."( Antagonism of bromobenzene-induced hepatotoxicity by the alpha-adrenoreceptor blocking agents phentolamine and idazoxan: role of hypothermia.
Harbison, RD; James, RC; Kerger, BD; Roberts, SM, 1989
)
0.64
"5 ml/kg dosage of bromobenzene."( Antagonism of bromobenzene-induced hepatotoxicity by the alpha-adrenergic blocking agents, phentolamine and idazoxan.
Bucci, TJ; Gandy, J; Harbison, RD; James, RC; Kerger, BD; Roberts, SM, 1988
)
0.97
" The use of non-fasted rats in acute oral toxicity determinations allows both the establishment of relative potency and the estimation of dosage levels for further repeated dose oral studies."( The effects of fasting on the acute oral toxicity of nine chemicals in the rat.
Dashiell, OL; Kennedy, GL, 1984
)
0.27
" Dosing rats with the gamma-glutamyl-transpeptidase inhibitor AT-125 results in the excretion of free glutathione in the urine of rat: this treatment did not lead to the excretion of glutathione conjugates of orally dosed xenobiotics, neither did AT-125 increase the biliary excretion of glutathione conjugates."( Effect of AT-125 on the metabolism of propachlor and the glutathione conjugates of propachlor and bromobenzene in rat.
Bakke, JE; Davison, KL; Larsen, GL, 1994
)
0.51
" The pathways from bromobenzene to phenols and to sulfur-containing metabolites derived from premercapturic acids show species and dosage variation."( Pathways of formation of 2-, 3- and 4-bromophenol from bromobenzene. Proposed mechanism for C-S lyase reactions of cysteine conjugates.
Horning, EC; Horning, MG; Lertratanangkoon, K, 1993
)
0.86
"0 ml/kg DMSO at 24 hr after toxicant dosing and then killing the animals at 48 hr."( Hepatoprotection by dimethyl sulfoxide. II. Characterization of optimal dose and the latest time of administration for effective protection against chloroform and bromobenzene induced injury.
Gandolfi, AJ; Lind, RC, 1999
)
0.5
" Time course experiments in mice were carried out in both tissues for each chemical and dose-response studies were used to further evaluate several of these chemicals."( Unique gene expression patterns in liver and kidney associated with exposure to chemical toxicants.
Bartosiewicz, MJ; Buckpitt, A; Emery, J; Jenkins, D; Penn, S, 2001
)
0.31
" Several examples of the utility of this approach from toxicological studies are presented as follows: interlaboratory variation in hydrazine response, CCl(4) dose-response relationships, and interspecies comparison of bromobenzene toxicity."( Geometric trajectory analysis of metabolic responses to toxicity can define treatment specific profiles.
Antti, H; Beckonert, O; Bollard, ME; Ebbels, TM; Holmes, E; Keun, HC; Lindon, JC; Nicholson, JK, 2004
)
0.51
" Male Han-Wistar rats were dosed with bromobenzene (1."( Integrated metabonomic analysis of bromobenzene-induced hepatotoxicity: novel induction of 5-oxoprolinosis.
Farrant, RD; Holmes, E; Nicholson, JK; Waterfield, CJ; Waters, NJ, 2006
)
0.88
" The sensitivity of the proposed method to detect changes in the NMR spectra 24 and 48 h after single dosing was compared with histopathology and biochemical parameters in plasma and urine."( Sensitivity of (1)H NMR analysis of rat urine in relation to toxicometabonomics. Part I: dose-dependent toxic effects of bromobenzene and paracetamol.
Horbach, GJ; Kloks, CP; Mellema, JR; Ploemen, JP; Schoonen, WG; Smit, MJ; Tas, AC; van Nesselrooij, JH; Vogels, JT; Zandberg, P; Zuylen, CT, 2007
)
0.55
" At 24 hr post-dose, hepatic injury was confirmed by monitoring the AST values and then the rats were maintained at the same dosing regimen for an additional 8 days."( Characterization of resistance to bromobenzene-induced hepatotoxicity by microarray.
Kiyosawa, N; Manabe, S; Tanaka, K; Watanabe, K, 2007
)
0.62
" In this metabolomics experiment the dosage and time-interaction effect were validated, both effects are significant."( Statistical validation of megavariate effects in ASCA.
Smilde, AK; van der Greef, J; Vis, DJ; Westerhuis, JA, 2007
)
0.34
" In this work, we focus on multifactorial time course microarray (MTCM) experiments with 2 factors: one quantitative such as time or dosage and the other qualitative, as tissue, strain, or treatment."( ARSyN: a method for the identification and removal of systematic noise in multifactorial time course microarray experiments.
Conesa, A; Ferrer, A; Nueda, MJ, 2012
)
0.38
" However, previous comparisons of the 2 technologies have not covered dose-response experiments that are relevant to toxicology."( Comparison of microarrays and RNA-seq for gene expression analyses of dose-response experiments.
Allen, BC; Black, MB; Chu, TM; Parks, BB; Pluta, L; Thomas, RS; Wolfinger, RD, 2014
)
0.4
" To determine the best way to select predictive groups of genes, we used published microarray data from dose-response studies on six chemicals in rats exposed orally for 5, 14, 28, and 90 days."( Recommended approaches in the application of toxicogenomics to derive points of departure for chemical risk assessment.
Barton-Maclaren, TS; Chepelev, NL; Curran, IH; Farmahin, R; Kuo, B; Nong, A; Thomas, RS; Wade, MG; Williams, A; Yauk, CL, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
non-polar solventnull
hepatotoxic agentA role played by a chemical compound exihibiting itself through the ability to induce damage to the liver in animals.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
bromobenzenesA member of the class of benzenes that is benzene substituted by at least one bromo group.
bromoareneA compound derived from an arene by replacing a hydrogen atom with a bromine atom.
volatile organic compoundAny organic compound having an initial boiling point less than or equal to 250 degreeC (482 degreeF) measured at a standard atmospheric pressure of 101.3 kPa.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.25890.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency50.11870.004023.8416100.0000AID485290
AR proteinHomo sapiens (human)Potency27.13950.000221.22318,912.5098AID743042
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency60.75780.003041.611522,387.1992AID1159552; AID1159555
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency44.66840.001024.504861.6448AID588535
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency25.11890.023723.228263.5986AID588543
gemininHomo sapiens (human)Potency0.81990.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mcl-1Homo sapiens (human)IC50 (µMol)54.00000.40007.134454.0000AID1418
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00052.773925.1700AID1418
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00052.891925.1700AID1418
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00052.747825.1700AID1418
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00052.780225.1700AID1418
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00053.314249.5000AID1418
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID1134601Hydrogen-bond basicity, pKHB of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID644414Lipophilicity, log D of the compound in octanol-water at pH 7.4 by reverse-phase HPLC analysis2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).
AID1367492Octanol-water partition coefficient, log P of the compound2017Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
Improvement in aqueous solubility achieved via small molecular changes.
AID1134600Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID1134599CHCl3-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
AID23443Partition coefficient (logP)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1134602Hexane-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (300)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990103 (34.33)18.7374
1990's68 (22.67)18.2507
2000's66 (22.00)29.6817
2010's54 (18.00)24.3611
2020's9 (3.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 77.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index77.04 (24.57)
Research Supply Index5.77 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index135.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (77.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (2.80%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other312 (97.20%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]